Table 1
Cost effectiveness in net costs per major outcome averted (in US$) for Amsterdam (Netherlands) of screening 15–25 year aged women (15–30 in parentheses) for asymptomatic Chlamydia trachomatis in systematic and opportunistic approaches for the baseline and in sensitivity analysis (PID risk at 10% instead of 20% in the baseline; assuming high performance testing*; and pooling†)
| Systematic | Opportunistic | |
|---|---|---|
| *PCR testing with sensitivity of 98.8% and specificity of 99.9%5; †pooling of urine specimens by five with relative sensitivity and specificity of 100%.5 | ||
| Baseline | 5300 (6300) | 1700 (3100) |
| PID risk at 10% | 11100 (12900) | 4100 (6900) |
| High performance testing | 4100 (4900) | 1300 (2600) |
| Pooling | 2000 (2400) | 500 (1200) |
